Cigna Group remains a Buy, with catalysts for double-digit adjusted income per share growth resuming in 2027 and beyond. CI's pharmacy segment, biosimilar adoption, behavioral health expansion, and aggressive share buybacks drive both topline and margin growth. Shares trade at an 8.5x forward P/E, a 29% discount to fair value, supporting a projected 17% annual total return through 2031.

Banque Pictet and Cie SA increased its position in shares of Cigna Group (NYSE: CI) by 40.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 25,216 shares of the health services provider's stock after purchasing an additional 7,204 shares during

Cigna (CI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

BLOOMFIELD, Conn., April 2, 2026 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) will release its first quarter 2026 financial results on Thursday, April 30, 2026, and will host a conference call the same day.

Exchange Traded Concepts LLC boosted its holdings in Cigna Group (NYSE: CI) by 31.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,539 shares of the health services provider's stock after buying an additional 2,055 shares during

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

apricus wealth LLC lifted its stake in shares of Cigna Group (NYSE: CI) by 715.9% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 9,505 shares of the health services provider's stock after buying an additional 8,340 shares during the period. apricus wealth

UBS analysts have outlined a set of high-conviction healthcare ideas where they believed the market was underappreciating earnings durability and the scale of upcoming catalysts, focusing on stocks backed by differentiated views and proprietary insights. In biotechnology, they identified Cogent Biosciences (NASDAQ:COGT) as their top pick, arguing the company offered scarcity value as a SMID-cap advancing two late-stage, potentially blockbuster assets.

Pallas Capital Advisors LLC raised its position in Cigna Group (NYSE: CI) by 133.1% during the undefined quarter, according to its most recent filing with the SEC. The institutional investor owned 4,774 shares of the health services provider's stock after acquiring an additional 2,726 shares during the period. Pallas Capital Advisors LLC's holdings

With grant funding, more than 20 nonprofit partners expanded access to stable housing and wraparound support services to support veteran communities in 10 states. Read the new Impact Report with outcomes in Arizona, Connecticut, Florida, Georgia, Illinois, Missouri, New Jersey, Pennsylvania, Tennessee and Texas.